GSA Capital Partners’s VYNE Therapeutics VYNE Stock Holding History

GSA Capital Partners’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-53,961	Closed	-$31K	–	2203
2025 Q4	$31K	Buy	53,961 +18,040	+50%	+$7.24K	﹤0.01%	1592
2025 Q3	$12K	Buy	35,921 +22,455	+167%	+$14.7K	﹤0.01%	1594
2025 Q2	$22K	Buy	+13,466	New	+$17.5K	﹤0.01%	1689
2022 Q2	–	Sell	-13,127	Closed	-$154K	–	1835
2022 Q1	$154K	Buy	13,127 +1,030	+9%	+$12.2K	0.02%	1227
2021 Q4	$222K	Buy	12,097 +6,964	+136%	+$149K	0.03%	1144
2021 Q3	$128K	Buy	+5,133	New	+$199K	0.01%	1302

Other funds holding VYNE

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

T3 Companies New York $76.8M AUM

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KCA

KVP Capital Advisors San Francisco, California $134M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GSA Capital Partners's VYNE Position: Q1 2026 in Review

GSA Capital Partners sold out of VYNE Therapeutics (VYNE) in Q1 2026, closing a stake of 53,961 shares — an estimated $31K sold.

GSA Capital Partners first reported a position in VYNE in Q3 2021 and held it in 6 quarters. The position peaked at $222K in Q4 2021. 45 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

GSA Capital Partners reported no remaining VYNE Therapeutics position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 53,961 VYNE Therapeutics shares in Q1 2026, an estimated $31K.
GSA Capital Partners first reported a position in VYNE Therapeutics in Q3 2021 and held it in 6 quarters.
GSA Capital Partners's VYNE Therapeutics position peaked at $222K in Q4 2021.
45 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.